147 related articles for article (PubMed ID: 38069574)
1. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
Ito K; Kawasaki T; Hirano K; Sekiguchi N
Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
[TBL] [Abstract][Full Text] [Related]
2. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1157-60. PubMed ID: 18326744
[TBL] [Abstract][Full Text] [Related]
3. Role of plasmapheresis in Waldenström's macroglobulinemia.
Stone MJ; Bogen SA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):238-40. PubMed ID: 23522642
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):100-3. PubMed ID: 19362987
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
6. The use of emergency apheresis in the management of plasma cell disorders.
Kalayoglu-Besisik S
Transfus Apher Sci; 2018 Feb; 57(1):35-39. PubMed ID: 29477943
[TBL] [Abstract][Full Text] [Related]
7. [Alleviation of ocular complications of the hyperviscosity syndrome in Waldenström's macroglobulinemia using plasma exchange].
Malecaze F; Mathis A; Gonzales C; Lloveras JJ; Goudable C; Arlet P; Bec P
J Fr Ophtalmol; 1986; 9(5):367-71. PubMed ID: 3100607
[TBL] [Abstract][Full Text] [Related]
8. Prediction of immunoglobulin M reduction via therapeutic dose of simple plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia.
Miyamoto Y; Hamasaki Y; Matsumoto A; Doi K; Noiri E; Nangaku M
J Clin Apher; 2018 Oct; 33(5):611-615. PubMed ID: 30188580
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
10. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
11. Plasma exchange in the long-term management of Waldenström's macroglobulinemia.
Buskard NA; Galton DA; Goldman JM; Kohner EM; Grindle CF; Newman DL; Twinn KW; Lowenthal RM
Can Med Assoc J; 1977 Jul; 117(2):135-7. PubMed ID: 406031
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic plasmapheresis in treatment of patients with Waldenström's macroglobulinemia.
Lawson NS; Nosanchuk JS; Oberman HA; Meyers MC
Transfusion; 1968; 8(3):174-8. PubMed ID: 4968993
[No Abstract] [Full Text] [Related]
14. Bilateral, persistent serous macular detachments with Waldenström's macroglobulinemia.
Pilon AF; Rhee PS; Messner LV
Optom Vis Sci; 2005 Jul; 82(7):573-8. PubMed ID: 16044069
[TBL] [Abstract][Full Text] [Related]
15. Histidine based adsorbents for selective removal of monoclonal immunoglobulin IgM antibodies from Waldenstrom's macroglobulinemia patient sera: a preliminary study.
Srour M; Kassab I; Matta H; Elkak A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():1-5. PubMed ID: 23811496
[TBL] [Abstract][Full Text] [Related]
16. Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia.
Stone MJ
Clin Lymphoma Myeloma; 2009 Mar; 9(1):97-9. PubMed ID: 19362986
[TBL] [Abstract][Full Text] [Related]
17. Hyperviscosity in plasma cell dyscrasias.
Kwaan HC
Clin Hemorheol Microcirc; 2013; 55(1):75-83. PubMed ID: 23455837
[TBL] [Abstract][Full Text] [Related]
18. Clinical and rheological studies in a patient with hyperviscosity syndrome due to Waldenström's macroglobulinemia.
Somer T; Ditzel J
Bibl Haematol; 1981; (47):242-6. PubMed ID: 6802129
[No Abstract] [Full Text] [Related]
19. Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type.
Höffkes HG; Heemann UW; Teschendorf C; Uppenkamp M; Philipp T
Clin Nephrol; 1995 May; 43(5):335-8. PubMed ID: 7634550
[TBL] [Abstract][Full Text] [Related]
20. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
